Amarin Corporation plc (AMRN)
-NasdaqGM 7.00 
0.05(0.71%) 10:02AM EDT - Nasdaq Real Time Price
| Prev Close: | 7.05 |
|---|
| Open: | 7.08 |
|---|
| Bid: | 7.00 x 13600 |
|---|
| Ask: | 7.01 x 800 |
|---|
| 1y Target Est: | 17.45 |
|---|
| Beta: | 0.91 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | 6.99 - 7.12 |
|---|
| 52wk Range: | 6.34 - 15.96 |
|---|
| Volume: | 1,904,653 |
|---|
| Avg Vol (3m): | 3,668,130 |
|---|
| Market Cap: | 1.05B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.04 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 2013 FDA Drug Approval Calendarat TheStreet(Tue 7:00AM EDT)
- Vascepa Data Should Make Amarin Longs Worriedat Seeking Alpha(Mon, May 20)
- Amarin: It's The Strategy, Not The Scienceat Seeking Alpha(Mon, May 20)
- AMARIN CORP PLC\UK FinancialsEDGAR Online Financials(Fri, May 17)
- A Disconnect Between Future Prospects of Drug Candidates Versus Where Share Price is Currently Trading: Portfolio Manager Finny Kuruvilla Discusses the Biotech and Pharmaceutical SectorsWall Street Transcript(Thu, May 16)
- Amarin & Celsion: Post-Earnings Roundupat Seeking Alpha(Wed, May 15)
- Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Groundat Seeking Alpha(Mon, May 13)
- Weekly Stock Watch - Week Of May 13, 2013at Seeking Alpha(Sat, May 11)
- 5 Stocks To Watch For Gains Next Weekat Seeking Alpha(Sat, May 11)
- Some Fish Oil Doesn't Help Some Patients in Some Countriesat Motley Fool(Sat, May 11)
- No Fat in This Drug Launchat Motley Fool(Fri, May 10)
- Analysts: Nvidia’s Stock Gains are Unjustified and 2 Other Research Notes to Browseat Wall St. Cheat Sheet(Fri, May 10)
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarinat TheStreet(Fri, May 10)
- Risky Amarin Sets Its Cash Pile On Fireat Seeking Alpha(Thu, May 9)
- Amarin Corporation CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 453.79 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.42 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.40 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | -0.07 |
|---|
Business Summary
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases.
View More